Conolidine’s analgesic effects stem from its interaction with non-opioid pain pathways. As opposed to opioids, which bind to µ-opioid receptors during the central nervous method, conolidine modulates alternate molecular targets. A Science Developments research uncovered that conolidine interacts Using the atypical chemokine receptor ACKR3/CXCR7,